Familial natural short sleep | |
---|---|
This condition is inherited as an autosomal dominant trait. | |
Specialty | Medical genetics |
Causes | Genetic mutation |
Prevention | none |
Familial natural short sleep is a rare, genetic, typically inherited trait where an individual sleeps for fewer hours than average without suffering from daytime sleepiness or other consequences of sleep deprivation. This process is entirely natural in this kind of individual, and it is caused by certain genetic mutations. [1] [2] [3] [4] A person with this trait is known as a "natural short sleeper". [5]
This condition is not to be confused with intentional sleep deprivation, which leaves symptoms such as irritability or temporarily impaired cognitive abilities in people who are predisposed to sleep a normal amount of time but not in people with FNSS. [6] [7] [8]
This sleep type is not considered to be a genetic disorder nor are there any known harmful effects to overall health associated with it; therefore it is considered to be a genetic, benign trait. [9]
Individuals with this trait are known for having the life-long ability of being able to sleep for a lesser amount of time than average people, usually 4 to 6 hours (less than the average sleeptime of 8 hours) each night while waking up feeling relatively well-rested, they also have a notable absence of any sort of consequence that derives from depriving oneself of sleep, something an average person would not be able to do on the sleeptime (and the frequency of said sleeptime) that is common for people with FNSS. [10] [11] [12] [13] [14]
Another common trait among people with familial natural short sleep is an increased ability at recalling memories. [15] Other common traits include outgoing personality, high productiveness, lower body mass index than average (possibly due to faster metabolism), higher resilience and heightened pain tolerance. [15] [16] [17] [12] [18] [19] All of these traits are of slightly better quality in people with natural short sleep than in people with natural normal sleep, essentially making them slightly more efficient than average people. [20] [21]
This condition is life-long, meaning that a natural short sleeper has naturally slept for a shorter time than average for most, if not all, of their lives. [22]
This trait is inherited as an autosomal dominant trait, which means that for a person to be a natural short sleeper, they must have at least one copy of a mutation related to this condition, this mutation must have been either inherited or it must have arisen from a spontaneous genetic error. [23] [24] A carrier for a mutation associated with FNSS has a 50% chance of transmitting the mutation to one of their offspring.
This condition has no known health complications associated with it.
A study done in 2001 showed that natural short sleepers are more prone to subclinical hypomania, [25] a temporary mental state most common during adolescence characterized by racing thoughts, abnormally high focus on goal-directed activities, unusually euphoric mood, and a perceptual innecessity for sleep. [26]
Five genes and around four to seven genetic mutations have been found to be implicated in the condition: [27] [28]
BHLHE41, also known as DEC2, [29] is a gene located in chromosome 12 which encodes a protein called "basic helix-loop-helix transcription factor repressor". The gene is known for influencing the mechanics of the circadian rhythm which in and of itself influences sleep patterns, specifically the amount of sleep one gets. [30] [31]
This missense mutation (also known as "rs121912617") is located in exon 5 of the gene and it consists of a G>C substitution in the coding region of DEC2 which results in a proline to arginine substitution at amino acid position 385 of the gene. [32] [33] [34] [35] This mutation impairs DEC2's ability at suppressing expression of the prepro-orexin, leading to higher expression of orexin. [36] [34] [37]
A mouse animal model was made in the same study that described the first 2 patients known to medical literature with the mutation; the mice that carried the mouse equivalent to the human DEC2-P385R mutation had, on average, about 1.2 hours more daytime activity than mice without the mutation. There were numerous other findings in the mutant mice, including an increased number of wakefulness episodes during a 12-hour time period compared to wild-type mice. [32]
This mutation has only been described in one of two dizygotic African-American twins. The affected twin was a 27-year old man who was found to have a non-synonymous mutation in amino acid position 362 in the fifth exon of the BHLHE41 gene which consisted of a substitution in the coding region of the gene from C>T which lead to an amino acid substitution of tyrosine to histidine. After deprivating them of sleep for over 38 hours, the researchers leading the study that described the pair of twins, total sleep time from both twins was measured; the results showed that the twin carrying the Y362H mutation had a recovering total sleep time of 482 minutes, while his twin slept for 572 minutes. Other findings in the Y362H twin included a higher delta power (measured with EEG) during NREM compared to his unaffected twin brother, resistance to the effects sleep deprivation has on one's neurobehavioral system, etc. [35]
ADRB1 is a gene located in chromosome 10 which encodes for the beta-1 adrenergic receptor protein. It plays a role in certain sleep patterns. [38] [39]
Only 4.028 out of every 100,000 people worldwide carry this mutation, it involves a C>T substitution in the coding region of ADRB1 which causes a substitution of alanine to valine in amino acid position 507 of the gene. [22] [40]
NPSR1 (formerly known as GPR154) is a gene located in chromosome 7. It encodes a plasma membrane protein which works as a neuropeptide S receptor of sorts, the function of the protein influences various cellular processes. [41]
This is a rare genetic mutation that has only been found in a man and his son, who slept between 4 and 5 hours a night each. This mutation consists of a substitution from tyrosine to histidine at amino acid position 206 of the gene. [42]
A mouse animal model in the same study that described the father and son showed that mutant mice (206H) slept, on average, around 71 minutes less than mice with the wild-type version (Y206) of the gene. They also found other characteristics in mutant mice, including high delta power during sleep, lesser memory deficits, etc. [42]
GRM1 is a gene located in chromosome 6, it encodes a protein called metabotropic glutamate receptor 1 whose main function is activating phospholipase C. [43]
This loss-of-function mutation is located in the C-terminal intracellular domain of the isoform mGluR1b in GRM1, it consists of a substitution from arginine to tryptophan at amino acid position 889 of the gene. The mutation impairs ERK activation. Only one family with the mutation has been officially described in the medical literature. [44]
Mouse animal models of the mutation showed that mice with the mutant allele (889W) slept on average 25 minutes less than mice with the wild-type (R889) allele, mutant mice also had a tendency to sleep less during their dark phase. [44]
This loss-of-function mutation is located in the large N-terminal extracellular domain of all GRM1 isoforms, and it consists of a substitution from serine to alanine at amino acid position 458 of the gene. The mutation impairs ERK activation. Only one family with the mutation has been officially described in the medical literature. [44]
Mouse animal models of the mutation showed that mice with the mutant allele (458A) slept on average 25 minutes less than mice with the wild-type (S458) allele, mutant mice also had a tendency to sleep less during their dark phase. [44]
Diagnosis is usually not necessary, as this trait is not considered a disorder in and of itself, however, there are various methods one's doctor can use to diagnose the condition, including but not limited to the use of questionnaires such as the morningness-eveningness questionnaire, the Munich chronotype questionnaire, etc. [45] [46] Clinical diagnostic methods for the condition include electroencephalograms, delta-power analyses, and genetic testing. [35]
There are other conditions similar to this specific trait that share some characteristics between each other, these include: [47]
List of conditions that may be confused with FNSS include:
It is estimated that approximately 1 to 3 percent of the population has the trait. [54] [55] In the U.S., natural short sleepers are a small part of a larger group comprising 30–35% of the population who sleep less than recommended. [56] [57] [58]
For some unknown reason, individuals with this condition (and their associated mutations) might be genetically protected against neurodegenerative disorders, mainly those that cause dementia, such as Alzheimer's disease. [59] [60] [61] [62]
Ying-Hui Fu did a study using animal mouse models who were genetically engineered to carry mutations associated with natural short sleep and mutations associated with an increased risk of suffering from dementia; the results showed that mice with both FNSS and dementia mutations did not show as much symptoms of dementia as their dementia-alone predisposed mice counterparts. [63] [64] [65] the same mice who had both Alzheimer's and short sleep gene mutations also had lesser amounts of Aβ plaque depositions in their hippocampuses and brain cortexes than those who only carried the Alzheimer's mutations. The FNSS-related mutations that were used in the study were DEC2-P384R and NPSR1-Y206H, and the Alzheimer's disease-related mutations were PS19 and 5XFAD. [66]
This condition first entered the medical literature in 2009 when Ying-Hui Fu, from the University of San Francisco, [67] described a woman and her daughter from the United States who manifested signs of the condition, the both of them slept for an average of 6 hours, while their unaffected family members slept from 7 to 9 hours a night. The mother, who was well into her 70s, reportedly had a very active and healthy lifestyle, and so did her daughter. [68] DNA sequencing done on them showed that a heterozygous mutation in their DEC2 gene, said mutation was later proved to be responsible for their short sleep phenotype through the use of mouse animal models. [32] [69] [70]
The ADRB1 gene mutation was discovered in 2019 by Ying-Hui Fu when she described a large, 5-generation family where the short sleeping phenotype segregated as an autosomal dominant trait in multiple members. After having SNP-based linkage analysis followed by whole-exome sequencing, the researchers leading the study found a rare genetic mutation in the family's ADRB1 gene that was present in affected family members but absent in otherwise unaffected family members. Like in the other study, mouse animal models confirmed the role this mutation had in the short sleep phenotype that segregated within the family. [22]
The NPSR1 gene mutation was discovered in 2019 by Ying-Hui Fu, her patients were a father and his son, both of whom had the short sleep phenotype. Whole-exome sequencing done on them afterwards revealed a heterozygous mutation in the NPSR1 gene which the both of them shared. Like in the last two studies, mouse animal models also helped confirm this mutation's involvement in the short-sleep phenotype. [42]
The GMR1 gene mutations were discovered in 2021, by Ying-Hui Fui, when she described affected members from 2 un-related families. [44]
Various famous/historical individuals have been known to sleep for 4 hours or less across human history, these include: [71] [72] [12] [73] [74] [75]
Fatal insomnia is an extremely rare neurodegenerative prion disease that results in trouble sleeping as its hallmark symptom. The majority of cases are familial, stemming from a mutation in the PRNP gene, with the remainder of cases occurring sporadically. The problems with sleeping typically start out gradually and worsen over time. Eventually, the patient will succumb to total insomnia, most often leading to other symptoms such as speech problems, coordination problems, and dementia. It results in death within a few months to a few years, and there is no known disease-modifying treatment.
Rett syndrome (RTT) is a genetic disorder that typically becomes apparent after 6–18 months of age and almost exclusively in females. Symptoms include impairments in language and coordination, and repetitive movements. Those affected often have slower growth, difficulty walking, and a smaller head size. Complications of Rett syndrome can include seizures, scoliosis, and sleeping problems. The severity of the condition is variable.
Advanced Sleep Phase Disorder (ASPD), also known as the advanced sleep-phase type (ASPT) of circadian rhythm sleep disorder, is a condition that is characterized by a recurrent pattern of early evening sleepiness and very early morning awakening. This sleep phase advancement can interfere with daily social and work schedules, and results in shortened sleep duration and excessive daytime sleepiness. The timing of sleep and melatonin levels are regulated by the body's central circadian clock, which is located in the suprachiasmatic nucleus in the hypothalamus.
Familial Mediterranean fever (FMF) is a hereditary inflammatory disorder. FMF is an autoinflammatory disease caused by mutations in Mediterranean fever gene, which encodes a 781–amino acid protein called pyrin. While all ethnic groups are susceptible to FMF, it usually occurs in people of Mediterranean origin—including Sephardic Jews, Mizrahi Jews, Ashkenazi Jews, Assyrians, Armenians, Azerbaijanis, Druze, Levantines, Kurds, Greeks, Turks and Italians.
Mismatch repair cancer syndrome (MMRCS) is a cancer syndrome associated with biallelic DNA mismatch repair mutations. It is also known as Turcot syndrome and by several other names.
Smith–Magenis syndrome (SMS), also known as 17p- syndrome, is a microdeletion syndrome characterized by an abnormality in the short (p) arm of chromosome 17. It has features including intellectual disability, facial abnormalities, difficulty sleeping, and numerous behavioral problems such as self-harm. Smith–Magenis syndrome affects an estimated between 1 in 15,000 to 1 in 25,000 individuals.
Ectrodactyly–ectodermal dysplasia–cleft syndrome, or EEC, and also referred to as EEC syndrome and split hand–split foot–ectodermal dysplasia–cleft syndrome is a rare form of ectodermal dysplasia, an autosomal dominant disorder inherited as a genetic trait. EEC is characterized by the triad of ectrodactyly, ectodermal dysplasia, and facial clefts. Other features noted in association with EEC include vesicoureteral reflux, recurrent urinary tract infections, obstruction of the nasolacrimal duct, decreased pigmentation of the hair and skin, missing or abnormal teeth, enamel hypoplasia, absent punctae in the lower eyelids, photophobia, occasional cognitive impairment and kidney anomalies, and conductive hearing loss.
Aarskog–Scott syndrome (AAS) is a rare disease inherited as X-linked and characterized by short stature, facial abnormalities, skeletal and genital anomalies. This condition mainly affects males, although females may have mild features of the syndrome.
Brunner syndrome is a rare genetic disorder associated with a mutation in the MAOA gene. It is characterized by lower than average IQ, problematic impulsive behavior, sleep disorders and mood swings. It was identified in fourteen males from one family in 1993. It has since been discovered in additional families.
The PER3 gene encodes the period circadian protein homolog 3 protein in humans. PER3 is a paralog to the PER1 and PER2 genes. It is a circadian gene associated with delayed sleep phase syndrome in humans.
PER2 is a protein in mammals encoded by the PER2 gene. PER2 is noted for its major role in circadian rhythms.
"Basic helix-loop-helix family, member e41", or BHLHE41, is a gene that encodes a basic helix-loop-helix transcription factor repressor protein in various tissues of both humans and mice. It is also known as DEC2, hDEC2, and SHARP1, and was previously known as "basic helix-loop-helix domain containing, class B, 3", or BHLHB3. BHLHE41 is known for its role in the circadian molecular mechanisms that influence sleep quantity as well as its role in immune function and the maturation of T helper type 2 cell lineages associated with humoral immunity.
Neurogenetics studies the role of genetics in the development and function of the nervous system. It considers neural characteristics as phenotypes, and is mainly based on the observation that the nervous systems of individuals, even of those belonging to the same species, may not be identical. As the name implies, it draws aspects from both the studies of neuroscience and genetics, focusing in particular how the genetic code an organism carries affects its expressed traits. Mutations in this genetic sequence can have a wide range of effects on the quality of life of the individual. Neurological diseases, behavior and personality are all studied in the context of neurogenetics. The field of neurogenetics emerged in the mid to late 20th century with advances closely following advancements made in available technology. Currently, neurogenetics is the center of much research utilizing cutting edge techniques.
Early-onset Alzheimer's disease (EOAD), also called younger-onset Alzheimer's disease (YOAD), is Alzheimer's disease diagnosed before the age of 65. It is an uncommon form of Alzheimer's, accounting for only 5–10% of all Alzheimer's cases. About 60% have a positive family history of Alzheimer's and 13% of them are inherited in an autosomal dominant manner. Most cases of early-onset Alzheimer's share the same traits as the "late-onset" form and are not caused by known genetic mutations. Little is understood about how it starts.
Maxillary lateral incisor agenesis (MLIA) is lack of development (agenesis) of one or both of the maxillary lateral incisor teeth. In normal human dentition, this would be the second tooth on either side from the center of the top row of teeth. The condition is bilateral if the incisor is absent on both sides or unilateral if only one is missing. It appears to have a genetic component.
Ying-Hui Fu is a Taiwanese-American biologist and human geneticist who has made important contributions to understanding the genetics of many neurological disorders. Her chief discoveries include describing Mendelian sleep phenotypes, identifying causative genes and mutations for circadian rhythm disorders, and characterizing genetic forms of demyelinating degenerative disorders. Fu is currently a professor of neurology at the University of California, San Francisco. She was elected to the US National Academy of Sciences in 2018.
Louis Ptáček is an American neurologist and professor who contributed greatly to the field of genetics and neuroscience. He was also an HHMI investigator from 1997 to 2018. His chief areas of research include the understanding of inherited Mendelian disorders and circadian rhythm genes. Currently, Ptáček is a neurology professor and a director of the Division of Neurogenetics in University of California, San Francisco, School of Medicine. His current investigations primarily focus on extensive clinical studies in families with hereditary disorders, which include identifying and characterizing the genes responsible for neurological variations.
Familial sleep traits are heritable variations in sleep patterns, resulting in abnormal sleep-wake times and/or abnormal sleep length.
Autosomal dominant leukodystrophy with autonomic disease is a rare neurological condition of genetic origin which is characterized by gradual demyelination of the central nervous system which results in various impairments, including ataxia, mild cognitive disability and autonomic dysfunction. It is part of a group of disorders called "leukodystrophies".
Calvarial doughnut lesions-bone fragility syndrome, also known as familial calvarial doughnut lesions, is a rare autosomal dominant genetic disorder characterized by mild to moderate fragility of the bones accompanied with calvarial doughnut lesions.
{{cite web}}
: CS1 maint: multiple names: authors list (link)